Hologic, Inc. Announces Offering of $1 Billion of Senior Notes
January 16, 2018 at 01:00 pm
Share
Hologic, Inc. announced a private offering of $1 billion aggregate principal amount of senior notes, to be allocated between additional 4.375% senior notes due 2025 and new senior notes due 2028. The Additional 2025 Notes will be issued as additional notes under the indenture governing the company’s 4.375% senior notes due 2025 dated October 10, 2017. The New 2028 Notes will be issued pursuant to a new indenture to be executed as of the closing of the Offering. The Additional 2025 Notes and the New 2028 Notes will be unsecured obligations of the Company and will be guaranteed by certain subsidiaries. The company intends to use the net proceeds of the Offering, plus available cash, including proceeds under its senior secured revolving credit facility, to redeem its outstanding 5.250% senior notes Due 2022 in the aggregate original principal amount of $1.0 billion. The company will redeem the 2022 Notes on February 15, 2018, subject to its completion of the Offering and the receipt of the proceeds thereof, for an aggregate redemption price equal to the principal amount thereof, plus the applicable premium and accrued and unpaid interest thereon through the day immediately preceding the redemption date.
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows:
- molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin;
- breast health (35.5%): digital mammography and breast biopsy solutions and systems;
- gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures;
- bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment.
Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%).
Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
HOLOGIC, INC. 
